Nectin4 (N4) is a biomarker that is overexpressed in ~62% of triple negative breast cancer (TNBC) and its lack of expression in normal tissues makes it an ideal target for the therapy and PET imaging of TNBC. Methods: We developed a fully human antibody against nectin 4 (anti N4) ...
Anti-Nectin-2 Antibody, Mouse Monoclonal 经验证的应用 应用推荐稀释比/用量 ELISA1:1000-1:2000 请注意:最佳浓度/稀释度应由用户决定。 Anti-Nectin-2 Antibody, Mouse Monoclonal: 别称 Anti-CD112 Antibody; Anti-HVEB Antibody; Anti-Nectin-2 Antibody; Anti-PRR2 Antibody; Anti-PVRL2 Antibody; Anti-...
The results indicated that Nectin-4 was expressed in clear cell variant tissues, while programmed cell death protein 1 (PD-1) and PD-L1 expression levels were weak in these tissues. The patient...
96,112CD155 has the highest affinity to TIGIT and lower affinity to CD96 and CD226. CD112 binds TIGIT and CD226 less strong than CD155, and does not bind CD96.96,112CD111 only interacts with and stabilizes CD155.113Nectin-4 only interacts with TIGIT...
et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int. Immunol. 16, 533–538 (2004). Article CAS PubMed Google Scholar Oshima, T. et al. Nectin-2 is a potential target for antibody therapy of breast and ...
Lung Cancer: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno REVIEW Danielle Brazel1, Sai-Hong Ignatius Ou 1,2, Misako Nagasaka 1–3 1Department of Medicine, ...
Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. PMID: 35614462 Antibody-based in vivo leukocyte label for two-photon brain imaging in mice. PMID: 35637871 In vivo application of mAb directed against the gammadelta TCR does not deplete but generate...
T cell function and fate can be influenced by several metabolites: in some cases, acting through enzymatic inhibition of α-ketoglutarate-dependent dioxygenases, in others, through post-translational modification of lysines in important targets. We show
Although chimeric antigen receptor (CAR) T cells are effective against B-lineage malignancies, post-CAR relapse is common, and efficacy in other tumors is limited. These challenges may be addressed through rational manipulations to control CAR T cell fun
(e.g., Anticalins®), EETI-II/AGRP, BPTI/LACI-D1/ITI-D2 (e.g., Kunitz domains), thioredoxin peptide aptamers, protein A (e.g., Affibody®), ankyrin repeats (e.g., DARPins), gamma-B-crystallin/ubiquitin (e.g., Affilins), CTLD3 (e.g., Tetranectins), Fynomers, and (...